Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: Kyowa Kirin Holdings B.V., Bloemlaan 2, 2132NP Hoofddorp, The Netherlands, Tel: +31 (0) 237200822
SANCUSO 3.1 mg/24 hours transdermal patch.
| Pharmaceutical Form |
|---|
|
Transdermal patch. Thin, translucent, matrix-type, rectangular-shaped transdermal patch with rounded corners. |
Each 52 cm² transdermal patch contains 34.3 mg of granisetron releasing 3.1 mg of granisetron per 24 hours.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Granisetron |
Granisetron is a potent anti-emetic and highly selective antagonist of 5-hydroxytryptamine (5HT3 receptors). Pharmacological studies have demonstrated that granisetron is effective against nausea and vomiting as a result of cytostatic therapy. |
| List of Excipients |
|---|
|
Backing layer: Polyester Matrix layer: Acrylate-vinylacetate copolymer Release liner: Siliconised polyester |
Each transdermal patch is packaged in a heat-sealed sachet composed of polyester-coated paper/aluminium/LLDPE.
Each carton contains 1 transdermal patch.
Kyowa Kirin Holdings B.V., Bloemlaan 2, 2132NP Hoofddorp, The Netherlands, Tel: +31 (0) 237200822
EU/1/12/766/001
Date of first authorisation: 20 April 2012
Date of latest renewal: 9 January 2017
| Drug | Countries | |
|---|---|---|
| SANCUSO | Austria, Estonia, Finland, France, Hong Kong, Croatia, Ireland, Italy, Lithuania, Netherlands, Poland, Romania, Singapore, Tunisia, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
